Mark P Hamilton, Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis, Nadia Kirmani, Zachary Ehlinger, Shriya Syal, Zinaida Good, Brian Sworder, Joseph Schroers-Martin, Ying Lu, Lori Muffly, Robert S Negrin, Sally Arai, Robert Lowsky, Everett Meyer, Andrew R Rezvani, Judith A Shizuru, Wen-Kai Weng, Parveen Shiraz, Surbhi Sidana, Sushma Bharadwaj, Melody Smith, Saurabh Dahiya, Bita Sahaf, David M Kurtz, Crystal L Mackall, Robert Tibshirani, Ash A Alizadeh, Matthew J Frank, David B Miklos
Chimeric antigen receptor (CAR) T cells directed against CD19 (CAR19) are a revolutionary treatment for B-cell lymphomas. CAR19 cell expansion is necessary for CAR19 function but is also associated with toxicity. To define the impact of CAR19 expansion on patient outcomes, we prospectively followed a cohort of 236 patients treated with CAR19 (brexucabtagene autoleucel or axicabtagene ciloleucel) for mantle cell (MCL), follicular (FL), and large B-cell lymphoma (LBCL) over the course of five years and obtained CAR19 expansion data using peripheral blood immunophenotyping for 188 of these patients...
March 18, 2024: Blood Advances